Abstract
A 54-year-old man was admitted to the intensive care unit six weeks after a myocardial infarction suffering from metabolic derangement secondary to rhabdomyolysis. There was no obvious precipitant for his condition, though he had recently had his atorvastatin dose increased from 10 mg to 80 mg and a number of new medications commenced. Extensive investigations failed to identify other causes of rhabdomyolysis and it was concluded that his condition related to a combination of statin therapy with other medications, namely the anti-staphylococcal agent fucidic acid. Despite discontinuation of his statin therapy, rhabdomyolysis persisted and the patient died from sepsis related to a prolonged ICU stay. This case highlights the potential risks of statin therapy, particularly in the critically ill patient population, where there may be significant interactions between statins and other co-prescribed medications. Such interactions can lead to impaired statin metabolism, potentially increasing the risks of rhabdomyolysis and other serious side effects.